NDAQ Stock Recent News

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Classover Holdings, Inc. (Nasdaq:KIDZ)(Nasdaq:KIDZW) ("Classover" or the "Company"), a leading provider of live, interactive online learning, today announced that it has been notified by Nasdaq that options on its Class B common stock have been approved for trading on multiple U.S. options exchanges. The options, which will trade under the ticker symbol "KIDZ", will feature a range of standard expiration dates and strike prices.

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 27 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first approved product, and the c.

DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,200 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Luxembourg, Grand Duchy of Luxembourg, June 6, 2025 (GLOBE NEWSWIRE) – Codere Online Luxembourg, S.A. (Nasdaq: CDRO / CDROW) (the “Company” or “Codere Online”), a leading online gaming operator in Spain and Latin America, today announced that it has received formal notification from the Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the Company's securities will continue to be listed and traded on the Nasdaq Capital Market and are no longer subject to a delisting process.

KYIV, Ukraine, June 05, 2025 (GLOBE NEWSWIRE) -- Kyivstar Group Ltd., Ukraine's leading digital operator (“Kyivstar Group” or “the Company”) and a subsidiary of VEON Ltd. (Nasdaq: VEON) (“VEON Group” or “VEON”), today announced the public filing of its Registration Statement on Form F-4 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”).

KYIV, Ukraine, June 05, 2025 (GLOBE NEWSWIRE) -- Kyivstar Group, Ukraine's leading digital operator (“Kyivstar Group” or “the Company”) and a subsidiary of VEON Ltd. (Nasdaq: VEON) (“VEON Group” or “VEON”), today announced its unaudited financial and operating results for the first quarter ended March 31, 2025.

BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compe

KYIV, Ukraine, June 5, 2025 – Kyivstar Group, Ukraine's leading digital operator (“Kyivstar Group” or “the Company”) and a subsidiary of VEON Ltd. (Nasdaq: VEON) (“VEON Group” or “VEON”), today announced its unaudited financial and operating results for the first quarter ended March 31, 2025.

REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4).